Caring for Patients in High-Consequence Infectious Disease Hot Zones
September 5th 2025In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.
The Aminoglyco-Side Hustle: What’s Now and Next in Gram-Negative Infections
September 5th 2025In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.
PCR Testing of Pneumonia in ICU Improves Treatment Costs but Not Cure Rate
September 4th 2025Compared to culture/sensitivity results (C/S) results, ICU-based PCR testing of hospital-acquired pneumonia was associated with lower treatment costs and better antibiotic stewardship, but not higher cure rates.
Florida Plans to End All Vaccine Mandates
September 3rd 2025This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.
Monitoring Drug-Resistant Strains of Malaria Utilizing Genomic Sequencing
September 2nd 2025Jonathan Parr, MD, MPH, discusses his research about this deadly and burdensome disease and how he and his team identify these parasitic strains with a combination of epidemiologic field work and the latest laboratory technology.
Practical Strategies to Minimize Antimicrobial Resistance in Patients With Critical Illness
August 31st 2025Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how clinicians can help reduce the emergence of antimicrobial resistance by using higher doses with extended infusions, limiting treatment duration, ensuring source control, and avoiding unnecessary dose reductions during CRRT.
High-Dose Influenza Vaccine vs Standard Dose: Hospitalization Outcomes in Older Adults
August 30th 2025Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.
How Should Individuals Interpret the FDA’s Latest COVID-19 Vaccine Authorization?
August 29th 2025Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.
FDA Approves Updated COVID-19 Vaccines for Fall 2025, Restricts Eligibility to High-Risk Groups
Published: August 29th 2025 | Updated: August 29th 2025New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
6th Death Reported in Harlem Legionnaires’ Outbreak as Bronx Cluster Investigated
Published: August 27th 2025 | Updated: August 27th 2025NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.
Insulating Infection Prevention: How Technology Can Help IP Teams Stay the Course
August 27th 2025Infection preventionists face constant regulatory, organizational, and infectious disease challenges, and leveraging evidence-based practices alongside surveillance technology helps them maintain consistency, resilience, and patient safety.
Biopreparedness Exercises Look to Contain High-Consequence Infectious Disease Outbreaks
August 26th 2025Leaders from the UNC Special Pathogens Response Center discuss how they plan and carry out biopreparedness trainings to address transport and care of patients with high-consequence infectious diseases, such as Ebola or Lassa fever.